Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy

Nature Reviews Urology

Volumn 6, Issue 7, 2009, Pages 375-383

  Jason Abel, E ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DRUG MEGADOSE; DRUG TARGETING; ELDERLY CARE; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; DRUG DELIVERY SYSTEM; KIDNEY TUMOR; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; KIDNEY NEOPLASMS; NEPHRECTOMY; PYRIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77949451507     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.102     Document Type: Review

References (83)

1. Janzen, N. K., Kim, H. L., Figlin, R. A. & Belldegrun, A. S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 30, 843-852 (2003).
2. Lane, B. R. & Kattan, M. W. Prognostic models and algorithms in renal cell carcinoma. Urol. Clin. North Am. 35, 613-625 (2008).
3. Yagoda, A., Petrylak, D. & Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20, 303-321 (1993).
4. Nelson, E. C., Evans, C. P. & Lara, P. N. Jr. Renal cell carcinoma: current status and emerging therapies. Cancer Treat. Rev. 33, 299-313 (2007).
5. Flanigan, R. C. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
6. Mickisch, G. H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
7. Latif, F. et al. Identification of the von Hippel- Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
8. Foster, K. et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169-2173 (1994).
9. Kim, W. Y. & Kaelin, W. G. Role of vHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
10. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
11. Escudier, B. et al. Sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
12. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 372, 449-456 (2008).
13. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
14. Rini, B. I. et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26, 5422-5428 (2008).
15. Rixe, O. et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase ii study. Lancet Oncol. 8, 975-984 (2007).
16. Sonpavde, G., Hutson, T. E. & Sternberg, C. N. Pazopanib, a potent orally administered smallmolecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Investig. Drugs 17, 253-261 (2008).
17. Middleton, R. G. Surgery for metastatic renal cell carcinoma. J. Urol. 97, 973-977 (1967).
18. Snow, R. M. & Schellhammer, F. Spontaneous regression of metastatic renal cell carcinoma. Urology 20, 177-181 (1982).
19. Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P. & Fleischmann, J. Cytoreductive surgery for stage iv renal cell carcinoma. J. Urol. 154, 32-34 (1995).
20. Flanigan, R. C. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
21. Rackley, R. et al. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J. Urol. 152, 1399-1403 (1994).
22. Fallick, M. L., McDermott, D. F., Larock, D., Long, J. P. & Atkins, M. B. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158, 1691-1695 (1997).
23. Walther, M. M., Yang, J. C., Pass, H. I., Linehan, W. M. & Rosenberg, S. A. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol. 158, 1675-1678 (1997).
24. Robertson, C. N. et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J. Urol. 144, 614-617 (1990).
25. Spencer, W. F. et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J. Urol. 147, 24-30 (1992).
26. Wagner, J. R. et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J. Urol. 162, 43-45 (1999).
27. Lara, N. Jr et al. Predictors of survival of advanced renal cell carcinoma: long-term results from southwest Oncology Group Trial s8949. J. Urol. 181, 512-516 (2009).
28. Rini, B. I. & Campbell, S. C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 177, 1978-1984 (2007).
29. Gatenby, R. A., Gawlinski, E. T., Tangen, C. M., Flanigan, R. C. & Crawford, E. D. The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer Res. 62, 5218-5222 (2002).
30. Rini, B. I. VeGF-targeted therapy in metastatic renal cell carcinoma. Oncologist 10, 191-197 (2005).
31. Kawata, N. et al. Histopathologic analysis of angiogenic factors in localized renal cell carcinoma: the influence of neoadjuvant treatment. Int. J. Urol. 8, 275-281 (2001).
32. Slaton, J. W. et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am. J. Pathol. 158, 735-743 (2001).
33. Margulis, V., Matin, S. F. & Wood, C. G. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Curr. Opin. Urol. 18, 474-480 (2008).
34. Motzer, R. J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
35. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
36. Mekhail, T. M. et al. Validation and extension of the Memorial sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
37. Halbert, R. J. et al. Treatment of patients with metastatic renal cell cancer: a rAND Appropriateness Panel. Cancer 107, 2375-2383 (2006).
38. Choueiri, T. K. et al. Clinical factors associated with outcome in patients with metastatic clearcell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550 (2007).
39. Kim, H. L. et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J. Urol. 173, 1496-1501 (2005).
40. Kim, H. L. et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. 10, 5464-5471 (2004).
41. Bui, M. H. et al. Carbonic anhydrase iX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003).
42. Atkins, M. et al. Carbonic anhydrase iX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005).
43. Deprimo, S. E. et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of veGF and veGFrelated proteins. J. Transl. Med. 5, 32 (2007).
44. Tatokoro, M. et al. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 180, 515-519 (2008).
45. Kassouf, W. et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol. 178, 1896-1900 (2007).
46. Abel, E. et al. Percutaneous primary tumor biopsy is unreliable to predict high risk pathologic features in patients with metastaic renal cell carcinoma [abstract 1401]. J. Urol. 181 (Suppl. 1), 501 (2009).
47. Shuch, B. Cytoreductive nephrectomy for patients with advanced kidney cancer and sarcomatoid histology: is up-front resection indicated, avoidable, and is there an alternative? [abstract 282]. Presented at the AsCO Genitourinary Cancers symposium, 2009 February 26-28, Orlando, FL, UsA.
48. Margulis, V., Tamboli, P., Matin, S. F., Swanson, D. A. & Wood, C. G. Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. Cancer 112, 1480-1488 (2008).
49. Motzer, R. J. et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381 (2002).
50. Choueiri, T. K. et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 127-131 (2008).
51. Kader, A. K. et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J. Urol. 177, 855-860 (2007).
52. Kassouf, W. et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M. D. Anderson Cancer Center experience. Urology 69, 835-838 (2007).
53. Matin, S. F., Madsen, L. T. & Wood, C. G. Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center experience. Urology 68, 528-532 (2006).
54. Walther, M. M., Lyne, J. C., Libutti, S. K. & Linehan, W. M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 53, 496-501 (1999).
55. Rabets, J. C. et al. Laparoscopic versus open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64, 930-934 (2004).
56. Capitanio, U. et al. Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a populationbased study. Urology 72, 1090-1095 (2008).
57. Hutterer, G. C. et al. Cytoreductive nephronsparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 110, 2428-2433 (2007).
58. Krambeck, A. E. et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J. Urol. 176, 1990-1995 (2006).
59. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. V2. 2009. National Comprehensive Cancer Network [online], http://www.nccn.org/ professionals/physician-gls/PDF/kidney.pdf (2009).
60. Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Longterm survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6 (Suppl. 1), s55-s57 (2000).
61. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
62. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 370, 2103-2111 (2007).
63. Biswas, S., Kelly, J. & Eisen, T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14, 52-59 (2009).
64. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
65. Jonasch, E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev. Anticancer Ther. 7, 73-78 (2007).
66. Jonasch, E. & Tannir, N. M. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J. 14, 315-319 (2008).
67. Baird, A. D., Woolfenden, K. A., Desmond, A. D., Fordham, M. V. & Parsons, K. F. Outcome and survival with nonsurgical management of renal cell carcinoma. BJU Int. 91, 600-602 (2003).
68. Jonasch, E. et al. Phase ii presurgical feasibility study of bevicizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. (in press).
69. Shuch, B. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 102, 692-696 (2008).
70. van der veldt, A. A. et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14, 2431-2436 (2008).
71. Thomas, A. A. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518-523 (2009).
72. Margulis, V. & Wood, C. G. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? Eur. Urol. 54, 489-492 (2008).
73. Bex, A., Horenblas, S., Meinhardt, W., verra, N. & de Gast, G. C. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur. Urol. 42, 570-574 (2002).
74. Bex, A. et al. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study. Eur. Urol. 49, 76-81 (2006).
75. Margulis, V. & Wood, C. G. Pre-surgical targeted molecular therapy in renal cell carcinoma. BJU Int. 103, 150-153 (2008).
76. Kabbinavar, F. et al. Phase ii, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (Lv) with FU/Lv alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65 (2003).
77. Margulis, V. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94-98 (2008).
78. Figlin, R. A. et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 158, 740-745 (1997).
79. Levy, D. A., Swanson, D. A., Slaton, J. W., Ellerhorst, J. & Dinney, C. P. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J. Urol. 159, 1168-1173 (1998).
80. Tigrani, V. S., Reese, D. M., Small, E. J., Presti, J. C. Jr & Carroll, P. R. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology 55, 36-40 (2000).
81. Mosharafa, A. et al. Nephrectomy for metastatic renal cell carcinoma: indiana University experience. Urology 62, 636-640 (2003).
82. Culp, S. H. et al. Identifying patients with metastatic renal cell carcinoma who will not benefit from cytoreductive nephrectomy [abstract 1394]. J. Urol. 181 (Suppl. 1), 498 (2009).
83. Atkins, M. Plenary session discussion of abstracts LBA3 and LBA4. Presented at AsCO Annual Meeting, 2006 June 2-6, Atlanta, GA, UsA.